Cochrane COVID-19 Study Register
NCT04355026

Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia

  1. Study Type
  2. Interventional
  1. Study Aim
  2. Treatment and Management
  1. Study Design
  2. Parallel/Crossover
  1. Intervention Assignment
  2. Randomised
  1. Population (8)
  2. Male and Female
  3. Hospitalization
  4. COVID-19
  5. Adult
  6. Aged (65+)
  1. Intervention (2)
  2. Hydroxychloroquine
  3. Bromhexine
  1. Comparison (1)
  2. Hydroxychloroquine
  1. Outcome (6)
  2. Nosocomial Pneumonia
  3. Oxygen Supplementation
  4. Length of ICU Stay
  5. Mechanical ventilation
  6. Duration Of Hospital Stay
  7. Duration of Symptom

Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia

General and Teaching Hospital Celje
First Published (first received 2020 April 21)ClinicalTrials.gov (https://clinicaltrials.gov/show/NCT04355026)
Trial registry record
No Results
In the current situation it is of great importance to discover a safe, cost-effective and available treatment strategy in order to limit the rapidly spreading SARS-Cov-2. Recent studies have shown that hydroxychloroquine could have a role in the treatment of infected patients. It is however not very likely that hydroxychloroquine alone could be adequate for treatment of Covid-19 disease. Effective therapy that prevents the virus entrance should contain at least TMPRSS2 inhibitor or a competitive inhibitor of viral ACE 2 binding. The use of bromhexine at the dose adequate to selectively inhibit the TMPRSS2, resulting in preventing of viral entrance via TMPRSS2-specific pathway, coud be an effective treatment of Covid-19. In our study we would like to explore the therapeutic potential of bromhexin and hydroxychloroquine in Covid-19 patients. Hypothesis 1. Combined treatment with bromhexin and hydroxychloroquine shortens the course of disease in hospitalized Covid-19 patients compared to hydroxychloroquine alone. 2. Combined treatment with bromhexin and hydroxychloroquine lowers the incidence of secundary pulmonary infections in hospitalized Covid-19 patients compared to hydroxychloroquine alone. 3. Combined treatment with bromhexin and hydroxychloroquine decreases the need for ICU admission in hospitalized Covid-19 patients compared to hydroxychloroquine alone